Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 803 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inherited Ophthalmic Diseases Clear all
Completed Phase 3 Interventional

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

NCT00750009
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
educational intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 4, 2026, 5:09 AM EDT
Completed No phase listed Observational

Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial Differences

NCT00340964
View directory record Official record
Conditions
Craniofacial Differences
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
12 Years to 20 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

NCT03507686
View directory record Official record
Conditions
Choroideremia
Interventions
BIIB111
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 4, 2026, 5:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

NCT03316560
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-RPGR
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
6 Years to 50 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Durham, North Carolina • Cincinnati, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 4, 2026, 5:09 AM EDT
Completed No phase listed Observational

Clinical and Pathophysiological Investigations Into Erdheim Chester Disease

NCT01417520
View directory record Official record
Conditions
Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS), Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 4, 2026, 5:09 AM EDT
Completed No phase listed Observational

Gyrate Atrophy of the Choroid and Retina

NCT00001166
View directory record Official record
Conditions
Gyrate Atrophy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 5:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

NCT07161544
View directory record Official record
Conditions
Stargardt Disease
Interventions
AAVB-039
Biological
Lead sponsor
AAVantgarde Bio Srl
Industry
Eligibility
8 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, AIN 457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 4, 2026, 5:09 AM EDT
Active, not recruiting No phase listed Observational

Natural History Study of Patients With Neurofibromatosis Type I

NCT00924196
View directory record Official record
Conditions
Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor, Plexiform Neurofibroma, Optic Glioma, Neurofibroma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Weeks and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 5:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

NCT07408232
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Phase 1b/2: Cohort 1 - OCT-980 Tablet, Phase 1b/2: Cohort 2 - OCT-980 Tablet, Phase 1b/2: Cohort 3 - OCT-980 Tablet, Phase 1b/2: Cohort 4 - OCT-980 Tablet, Phase 1b/2: Cohort 5 - OCT-980 Tablet
Drug
Lead sponsor
Octant, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 4, 2026, 5:09 AM EDT
Terminated Phase 1Phase 2 Interventional

Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

NCT05392751
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis Pigmentosa Syndrome
Interventions
EA-2353
Drug
Lead sponsor
Endogena Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 4, 2026, 5:09 AM EDT
Withdrawn Not applicable Interventional

Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy Multicenter Study

NCT02548572
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Transcorneal Electrical Stimulation using Okustim device
Device
Lead sponsor
Wills Eye
Other
Eligibility
22 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 4, 2026, 5:09 AM EDT
Terminated No phase listed Observational

New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System

NCT01860092
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Second Sight Medical Products
Industry
Eligibility
25 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Study of STG-001 in Subjects With Stargardt Disease

NCT04489511
View directory record Official record
Conditions
Stargardt Disease-1
Interventions
STG-001
Drug
Lead sponsor
Stargazer Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Gainesville, Florida • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation

NCT03133767
View directory record Official record
Conditions
Fluid Loss, Symptom Complex, Triple, Emergencies
Interventions
Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag
Drug
Lead sponsor
Nicholas M Mohr
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 4, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Heidelberg Engineering ANTERION Imaging Agreement Study

NCT04068818
View directory record Official record
Conditions
Eye Abnormalities, Normal Eyes
Interventions
ANTERION
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 4, 2026, 5:09 AM EDT
Completed No phase listed Observational

Biomarkers In Retinitis Pigmentosa (BIRP)

NCT01949623
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Anterior Chamber (AC) tap
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 4, 2026, 5:09 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa (XLRP)
Interventions
Adeno-associated virus vector expressing a human RPGR gene
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Rituximab for Graves' Ophthalmopathy

NCT00595335
View directory record Official record
Conditions
Thyroid-associated Ophthalmopathy
Interventions
Rituximab, Saline, Methylprednisolone
Drug
Lead sponsor
Rebecca Bahn
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Combined Cataract Surgery and Planned Descemetorhexis

NCT02206594
View directory record Official record
Conditions
Fuchs' Corneal Dystrophy, Cataract
Interventions
Descemetorhexis
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 4, 2026, 5:09 AM EDT
Completed No phase listed Observational

VCRC Patient Contact Registry Patient-Reported Data Validation Study

NCT02190942
View directory record Official record
Conditions
Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

NCT04246866
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
Interventions
GEM103
Biological
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 4, 2026, 5:09 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation

NCT02911805
View directory record Official record
Conditions
Vision Disorders
Interventions
Aerobic exercise, Balance exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

NCT02140151
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Southern California Desert Retina Consultants, MC
Other
Eligibility
50 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 4, 2026, 5:09 AM EDT